A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2011
At a glance
- Drugs Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Aug 2010 Actual end date (1 Jun 2010) added as reported by ClinicalTrials.gov.
- 03 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.